Corbus Pharmaceuticals Holdings (CRBP) Net Equity Issued and Repurchased (2013 - 2025)

Corbus Pharmaceuticals Holdings' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $2.9 million for Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased fell 91.99% year-over-year to $2.9 million in Q3 2025; TTM through Sep 2025 was $2.8 million, a 98.44% decrease from a year earlier, with the FY2024 full-year figure at $182.1 million, up 343405.66% from the prior year.
• Net Equity Issued and Repurchased rose to $2.9 million in Q3 2025 per CRBP's latest filing, from -$13000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $108.9 million in Q1 2024 and bottomed at -$74000.0 in Q4 2023.
• The 4-year median for Net Equity Issued and Repurchased is $1.5 million (2023), against an average of $24.7 million.
• Across the five-year window, Net Equity Issued and Repurchased jumped 508471.43% in 2024 and plunged 91.99% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $62.5 million in 2021, then tumbled by 100.12% to -$74000.0 in 2023, then surged by 82.43% to -$13000.0 in 2024, then surged by 22030.77% to $2.9 million in 2025.
• Per Business Quant, the three latest CRBP Net Equity Issued and Repurchased figures stand at $2.9 million (Q3 2025), -$13000.0 (Q4 2024), and $35.6 million (Q3 2024).